Results 71 to 80 of about 1,506 (115)

RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases. [PDF]

Cell Death Dis
Regua AT, Bindal S, Najjar MK, Tran PL, Cha J, Shams SS, Lo HW.   +6 more
europepmc   +1 more source

Induction therapy of pralsetinib followed by conversion surgery for unresectable locally advanced non-small cell lung cancer with the rearranged during transfection (RET) fusion gene mutation: protocol for a single-arm phase II prospective trial (the SALVAGE-P trial). [PDF]

J Thorac Dis
Deng HY, Qiu XM, Li L, Tang XJ, Zhou Q.
europepmc   +1 more source

Response to Selpercatinib in a <i>CCDC6-RET</i> Lung Adenocarcinoma with an Acquired Novel <i>RET</i> p.L730_G731insL After Progression on Pralsetinib: A Case Report. [PDF]

Lung Cancer (Auckl)
Tian C, Zou Y, Liu J, Zhao J, Tian S, Liu Y, Wang G.   +6 more
europepmc   +1 more source

Development and Characterization of a Patient-Derived <i>KIF5B-RET</i> Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice. [PDF]

JTO Clin Res Rep
Nishiyama A, Sato S, Sakaguchi H, Kotani H, Yamashita K, Ohtsubo K, Nanjo S, Yano S, Mizuguchi K, Ikeda H, Yamaguchi M, Ishizuka T, Baba S, Takeuchi K, Takeuchi S.   +14 more
europepmc   +1 more source

<i>RET</i> fusion partners dictate oncogenic potential in undifferentiated spindle cell sarcomas. [PDF]

Cancer Biol Ther
Gui Q, Zhang Y, Yang M, Liang R, Huang M, Yang X, Chen N, Chen X, Wu M, Chen H, Meng L, Xiao S, Tao M.   +12 more
europepmc   +1 more source

Targeting Oncogenic Gene Fusions in Lung Cancer. [PDF]

Cancer J
Nie Y, Wilson FH.
europepmc   +1 more source

Pralsetinib-Induced Lymphocytic Colitis. [PDF]

ACG Case Rep J
Jin MF, Tawfic SS, Wang XJI.
europepmc   +1 more source

Pathological complete response in <i>RET</i>-positive non-small cell lung cancer: a case report of pralsetinib-based "sandwich" therapy. [PDF]

Transl Lung Cancer Res
He Q, Xu X, Li D, Zhang Y.
europepmc   +1 more source

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer. [PDF]

J Clin Oncol
Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazières J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF.   +30 more
europepmc   +1 more source

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. [PDF]

Clin Cancer Res
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ.   +37 more
europepmc   +1 more source